Dilution case studies · 9 min read
Warrant Inducement Offers Explained Through Decoy Therapeutics’ September 2026 Deal
How Decoy Therapeutics’ Sept 2026 warrant inducement repriced warrants to $3.25, added 2.37M new warrants, and where each step appears in SEC filings.
As of October 5, 2026. All figures below come from Decoy Therapeutics’ SEC filings listed at the end. Share counts reflect the company’s reverse stock splits (1-for-15 effective August 18, 2025, and 1-for-12 effective March 6, 2026), as the filings themselves do.
On September 22, 2026, Decoy Therapeutics (Nasdaq: DCOY), formerly Salarius Pharmaceuticals, signed a warrant inducement letter with one institutional holder. In about 24 hours, the holder exercised warrants it had bought three months earlier, the exercise price dropped from $5.91 to $3.25, two other warrant series were repriced the same way, and the holder received new warrants for twice as many shares as it had just exercised.
That is the standard shape of a warrant inducement. If you want the general mechanics first, learn them in the FennEdge dilution course, especially the lesson Warrants and convertibles. In short, a company gives a warrant holder a reason to exercise now, usually a lower strike plus new warrants, in exchange for immediate cash. This post follows one real deal through the filings, step by step.
Step 1: Where the warrants came from (June 2026)
The warrants in this deal were created in a private placement announced in an 8-K filed June 29, 2026:
- One institutional investor bought 592,217 shares (or pre-funded warrants in lieu of shares) at $5.91, for gross proceeds of about $3.5 million (592,217 × $5.91 = $3,500,002).
- It also received three series of milestone-based warrants, all with a $5.91 strike:
- Series A: 100% of the shares bought = 592,217
- Series B: 200% = 1,184,434
- Series C: 200% = 1,184,434
- Per the June 8-K and the later resale prospectus, the warrants became exercisable once stockholders approved the underlying share issuance. Each series also has a clinical or regulatory milestone event that starts an expiry clock: a series expires on the earlier of the 90th day after its milestone event and June 2031. For Series B, the milestone was notice of written approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for a Phase 2a human challenge trial. In effect, the milestone forces a decision: exercise within 90 days or lose the warrant.
- The 8-K said full cash exercise of all milestone warrants could bring up to about $17.5 million (2,961,085 warrant shares × $5.91 = $17,500,012).
A resale registration statement followed (S-1 File No. 333-297381, filed July 10 and declared effective July 17, 2026; prospectus filed as a 424B3). It registered up to 3,766,500 shares: 592,217 underlying pre-funded warrants, 2,961,085 underlying the milestone warrants, and 213,198 underlying placement agent warrants. Two things follow. Per the registered amounts, and consistent with the 590,185 shares on the September meeting’s record date, the June investor’s 592,217 “shares” appear to have been taken as pre-funded warrants rather than common stock. And the shares issued on exercise of the milestone warrants could be resold under an effective registration statement.
On September 14, 2026, stockholders approved the issuance of shares on exercise of the milestone warrants, as required by Nasdaq Listing Rules 5635(b) and 5635(d), per the 8-K filed September 15.
A wording inconsistency to note. The resale prospectus’s summary and its description of the private placement say the milestone warrants become exercisable upon stockholder approval, with the milestone event setting the 90-day expiry. One footnote to its selling stockholder table, however, says they are not exercisable until the milestone events are satisfied and stockholder approval is obtained. The filings we reviewed do not say whether the Series B MHRA milestone had occurred by September 22. The inducement letter states that the holder exercised Series B in full, which is consistent with the approval-based description. We do not infer more than that.
Step 2: The inducement terms (September 22, 2026)
From the September 23 8-K and the inducement letter (Exhibit 10.1):
| Term | Before | After |
|---|---|---|
| Series B strike (1,184,434 warrant shares) | $5.91 | $3.25, exercised in full for cash |
| Series A strike (592,217) | $5.91 | $3.25, not exercised; other terms unchanged |
| Series C strike (1,184,434) | $5.91 | $3.25, not exercised; other terms unchanged |
| New warrants | none | 2,368,868 at $3.25, exercisable immediately, 5-year term, 9.99% ownership blocker, unregistered (Section 4(a)(2)) |
| Gross proceeds | none | $3,849,410 before placement agent fees and expenses |
| Closing | n/a | September 23, 2026 |
Proceeds check: 1,184,434 × $3.25 = $3,849,410.50. The letter states $3,849,410.
The ratio: 2,368,868 ÷ 1,184,434 = 2.00. The holder received two new warrant shares for each warrant share it exercised. The 8-K calls it “200%.”
The price cut: $3.25 ÷ $5.91 = 0.550, a 45.0% lower strike. At the original $5.91 strike, the same 1,184,434 Series B warrant shares would have produced about $7.0 million (1,184,434 × $5.91 = $6,999,005). Whether they would ever have been exercised at $5.91 is unknowable, so treat that figure as a reference point, not a loss.
Restrictions in the letter: subject to exceptions, no new common stock or common stock equivalents and no new registration statements for 30 days after the letter, and no variable rate transactions until 180 days after the resale registration for the new warrant shares becomes effective. The letter’s definition of variable rate transaction includes equity lines and ATMs, with a carve-out for an ATM run through the placement agent starting 30 days after effectiveness.
Step 3: What happened to the share count
This is where traders often over-simplify, so we will be careful.
The base. The 10-Q cover reported 655,185 shares of common stock outstanding as of August 11, 2026. (The September special meeting record date, July 20, 2026, listed 590,185 shares. The filings do not reconcile the two dates; we cite both.)
The exercise. The exercise covered 1,184,434 underlying shares. That is 1,184,434 ÷ 655,185 = 180.8% of the August 11 share count.
But not necessarily all as common shares at once. The inducement letter includes a 9.99% beneficial-ownership limit. If delivering all the shares would push the holder above 9.99%, the company issues only up to the limit and holds the balance “in abeyance” until the holder asks for it. The June warrant terms also let the holder take pre-funded warrants instead of shares. So the right statement is that the exercise created a claim on 1,184,434 shares, deliverable over time as common stock or pre-funded warrants. The next 10-Q cover page will show how many common shares are actually outstanding.
The new overhang. After the deal, this one investor’s remaining warrants at a $3.25 strike, all from the filings:
| Warrant | Underlying shares | Status per filings |
|---|---|---|
| New warrants (Sept 2026) | 2,368,868 | Exercisable immediately |
| Series A milestone | 592,217 | Repriced; exercisable since the Sept 14 approval per the prospectus’s main description; expires 90 days after its milestone event, or in June 2031 |
| Series C milestone | 1,184,434 | Same as Series A, with its own milestone event |
| Total | 4,145,519 |
4,145,519 ÷ 655,185 = 6.33 times the August 11 share count. If every one of those warrants were exercised for cash at $3.25, the company would receive 4,145,519 × $3.25 = $13.47 million. That is a hypothetical ceiling, not a projection. The holder may never exercise, Series A and C may expire 90 days after their milestone events if not exercised, cashless exercise would bring in no cash, and the 9.99% blocker limits how much the holder can own at one time.
The 10-Q also lists other warrants outstanding from a November 2025 offering, which this deal did not change. Read the 10-Q’s equity footnote for those.
Step 4: The corrective press release
Decoy filed two press releases as exhibits. The original (Exhibit 99.1) said the new warrants would become exercisable only after stockholder approval, with a 5-year term starting from that date. The corrective release (Exhibit 99.2), dated the same day, said that was wrong: the new warrants are not subject to stockholder approval and are exercisable immediately on issuance.
For a trader, that correction changes the timeline. “Exercisable after a future vote” means the new shares are months away at minimum. “Exercisable immediately” means they are available as soon as a resale registration is effective or another resale route exists. The 8-K text matched the corrected version. When a press release and the 8-K disagree, read the 8-K and the exhibits.
Step 5: How each piece shows up in EDGAR
| What to look for | Where it appeared in this deal |
|---|---|
| Inducement agreement | 8-K Item 1.01, with the letter as Exhibit 10.1 |
| New unregistered warrants | 8-K Item 3.02 (unregistered sale), warrant form as Exhibit 4.1 |
| Press releases | 8-K Item 7.01, Exhibits 99.1 / 99.2 |
| Registration of the exercised warrant shares | Already covered: S-1 File No. 333-297381, effective July 17, 2026 |
| Registration of the new warrant shares | Company agreed to file a resale registration statement within 15 calendar days of September 22, which falls on October 7, 2026. As of October 5, 2026, it had not appeared in the company’s EDGAR filing list. |
| Actual shares issued | Next Form 10-Q cover page and equity footnote |
The usual sequence for inducements is: 8-K with the letter, then a resale S-1 or S-3 for the new warrant shares, then a 424B3 prospectus once that registration is effective. Decoy’s case followed the first step. Watch for the second.
What traders can take from this case
These are observations about the filings, not predictions about the stock.
- Strike resets change the math on every related series. Only Series B was exercised, but Series A and C were also cut to $3.25. Check all series named in the letter, not only the one being exercised, and check what starts each series’ expiry clock.
- The “200%” is the number of new warrant shares, not proceeds. The company received cash for 1,184,434 shares and issued rights to 2,368,868 more.
- Ownership blockers spread issuance over time. An exercise much larger than the outstanding share count usually reaches the market as common stock in steps, not all at once.
- Registration status sets the clock. The exercised shares were already registered for resale. The new warrant shares were not yet registered as of October 5.
- Restrictions are in the letter, not the press release. The 30-day standstill and 180-day variable-rate ban appear in the 8-K and Exhibit 10.1.
Checklist for the next inducement you see
- Old strike, new strike, and how many warrant shares were exercised
- New warrant count, ratio, strike, term, and when they become exercisable
- Any other series repriced in the same letter
- Gross proceeds (exercise count × new strike) and placement agent fees
- Ownership blocker percentage and any “abeyance” language
- Registration status of the exercised shares and the deadline for the new resale registration
- Standstill and variable rate transaction restrictions
- The latest share count from the most recent 10-Q or 10-K cover, with its date
This article is for information and education. It is not investment, legal, or tax advice, and it does not recommend any security or trade.
Related reading
To keep checking related concepts, read Offerings, dilution and reverse splits, Shelf registration, S-3, ATM and baby shelf, Equity lines: the Tempest Therapeutics case; the FennEdge dilution course; and the trading glossary.
Sources
- Decoy Therapeutics, Form 8-K (filed Sept 23, 2026), with Exhibit 10.1, Exhibit 99.1, and Exhibit 99.2
- Decoy Therapeutics, Form 8-K, private placement (filed June 29, 2026)
- Decoy Therapeutics, Form 424B3 resale prospectus (filed July 17, 2026)
- Decoy Therapeutics, Form 10-Q for Q2 2026 (filed Aug 12, 2026)
- Decoy Therapeutics, Form 8-K, special meeting results (filed Sept 15, 2026)
- SEC EDGAR, Decoy Therapeutics filing index (checked Oct 5, 2026)
This article explains common concepts; examples are not trading recommendations.
